[Featured Stock] MedPacto Falls on News of Withdrawal from Phase 2 Clinical Trial for Desmoid Tumor
![[Featured Stock] MedPacto Falls on News of Withdrawal from Phase 2 Clinical Trial for Desmoid Tumor](http://www.asiae.co.kr/news/img_view.htm?img=2022052410120678096_1653354727.jpg)
[Asia Economy Reporter Lee Jung-yoon] MedPacto is showing a downward trend on the 24th after announcing the withdrawal of its Phase 2 clinical trial related to desmoid tumors, for which it had received Investigational New Drug (IND) approval and was preparing.
As of 10:08 AM on the day, MedPacto is trading at 28,750 KRW, down 5.12% from the previous day.
The previous day, MedPacto disclosed that it voluntarily withdrew the Phase 2 clinical trial comparing the combination therapy of Bactosertib and Imatinib versus Imatinib monotherapy (MP-VAC-206) for progressive desmoid tumors (aggressive fibromatosis). This clinical trial had been approved by the Ministry of Food and Drug Safety in November last year.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Iranian Military Spokesperson: "Ceasefire Was an Opportunity to Strengthen Forces... Ready to Respond to War"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company explained, "We have revised our strategy to focus our capabilities on clinical trials for cancer types that can be commercialized early, leading to a portfolio adjustment regarding the Bactosertib clinical trial."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
